Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.

Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC.

J Clin Invest. 2019 Jul 15;130. pii: 126022. doi: 10.1172/JCI126022. eCollection 2019 Jul 15.

PMID:
31305264
Free Article
2.

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.

Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Carmagnani Pestana R, Vauthey JN, Allison JP, Sharma P.

Cancer Immunol Res. 2019 Jul 9. pii: canimm.0605.2018. doi: 10.1158/2326-6066.CIR-18-0605. [Epub ahead of print]

PMID:
31289040
3.

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review.

El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G.

J Adv Res. 2019 Mar 7;17:43-48. doi: 10.1016/j.jare.2019.03.001. eCollection 2019 May. Review.

4.

Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study.

Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM.

J Comput Assist Tomogr. 2019 May 6. doi: 10.1097/RCT.0000000000000866. [Epub ahead of print]

PMID:
31082984
5.

Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study.

Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM.

J Comput Assist Tomogr. 2019 May/Jun;43(3):499-506. doi: 10.1097/RCT.0000000000000866.

PMID:
31082956
6.

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.

Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ.

JAMA Oncol. 2019 Apr 18. doi: 10.1001/jamaoncol.2019.0270. [Epub ahead of print]

PMID:
30998813
7.

Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.

Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S.

Radiother Oncol. 2019 Apr;133:54-61. doi: 10.1016/j.radonc.2018.10.041. Epub 2019 Jan 16.

PMID:
30935582
8.

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma.

Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A.

Oncotarget. 2018 Dec 28;9(102):37721-37732. doi: 10.18632/oncotarget.26507. eCollection 2018 Dec 28.

9.

Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.

Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP.

Am J Gastroenterol. 2019 Feb;114(2):250-257. doi: 10.1038/s41395-018-0383-2.

PMID:
30410039
10.

Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry.

Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):451-461. doi: 10.1016/j.ijrobp.2018.05.062. Epub 2018 Jun 2.

PMID:
30191875
11.

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma.

Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ.

Cancer Med. 2018 Oct;7(10):4880-4892. doi: 10.1002/cam4.1734. Epub 2018 Aug 27.

12.

Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study.

Hosry J, Angelidakis G, Kaseb A, Jiang Y, Torres HA.

Clin Infect Dis. 2018 Oct 30;67(10):1635-1636. doi: 10.1093/cid/ciy387. No abstract available.

PMID:
30124786
13.

Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer.

Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA.

J Hepatocell Carcinoma. 2018 Aug 2;5:81-86. doi: 10.2147/JHC.S164568. eCollection 2018.

14.

Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance.

Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM.

J Hepatocell Carcinoma. 2018 Jun 27;5:61-73. doi: 10.2147/JHC.S156701. eCollection 2018. Review.

15.

Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases.

Ganeshan D, Szklaruk J, Kaseb A, Kattan A, Elsayes KM.

Abdom Radiol (NY). 2018 Dec;43(12):3340-3348. doi: 10.1007/s00261-018-1657-2.

PMID:
29948061
16.

Editorial: charting the future of hepatocellular carcinoma publications.

Kaseb AO.

J Hepatocell Carcinoma. 2018 May 8;5:51-54. doi: 10.2147/JHC.S159650. eCollection 2018. No abstract available.

17.

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma.

Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, Qayyum A, Kaseb A, Sheth RA.

J Clin Med. 2018 Apr 14;7(4). pii: E83. doi: 10.3390/jcm7040083.

18.

Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus.

Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, Minsky BD, Herman JM, Kaseb A, Raghav K, Conrad C, Vauthey JN, Aloia TA, Chun YS, Crane CH, Koay EJ.

Clin Transl Radiat Oncol. 2017 Jun 7;4:39-45. doi: 10.1016/j.ctro.2017.04.003. eCollection 2017 Jun.

19.

Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.

Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC).

Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13. Erratum in: Lancet Gastroenterol Hepatol. 2018 Jun;3(6):e3.

PMID:
29548617
20.

Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers.

Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J.

Trends Mol Med. 2018 Apr;24(4):395-411. doi: 10.1016/j.molmed.2018.02.006. Epub 2018 Mar 9. Review.

PMID:
29530485

Supplemental Content

Loading ...
Support Center